Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma  

作　　者：Michael T.Serzan Michael B.Atkins 

机构地区：[1]Georgetown Lombardi Comprehensive Cancer Center,Washington,DC 20057,USA.

出　　处：《Journal of Cancer Metastasis and Treatment》2021年第1期532-550,共19页癌症转移与治疗（英文版）

摘　　要：The therapeutic landscape for advanced clear cell renal cell carcinoma(ccRCC)is rapidly evolving with improved knowledge of the biology of disease leading to the incorporation of a variety of antiangiogenic agents and immunotherapies.In this review,we discuss historical,current,and emerging first line treatment options for patients with advanced ccRCC.These include data with single agent vascular endothelial growth factor receptor tyrosine kinase inhibitors(TKIs):sunitinib,pazopanib and cabozantinib as well as the recently reported results for the combination of lenvatinib and everolimus(mTOR inhibitor).We also discuss results of the nivolumab anti-programmed cell death(PD-1)/ipilimumab(anti-cytotoxic T lymphocyte-associated antigen 4)combination as well as emerging front-line data with nivolumab and pembrolizumab(anti-PD-1)monotherapy.Finally,we review data supporting recent approvals of TKI and anti-PD-1 or anti-PD-Ligand 1(PD-L1)combinations(e.g.,axitinib/pembrolizumab,axitinib/avelumab and cabozantinib/nivolumab)and initial outcomes of lenvatinib(multi-kinase inhibitor)and pembrolizumab.With many individual and combination treatment options and the lack of head-to-head comparisons,treatment selection will depend on the goals of therapy(endpoints)and the identification and validation of clinical and tumor-based predictive biomarkers that are linked to the desired treatment endpoints.

关 键 词：Renal cell carcinoma nivolumab IPILIMUMAB AXITINIB pembrolizumab avelumab biomarkers 

分 类 号：R73[医药卫生—肿瘤]